Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Gökmen-Polar Y[au]:

Tumor Heterogeneity in Breast Cancer. Badve S et al. Adv Anat Pathol. (2015)

Role of lncRNAs in health and disease-size and shape matter. Mohanty V et al. Brief Funct Genomics. (2015)

Multiplexed protein analysis. Gökmen-Polar Y et al. Sci Transl Med. (2014)

Search results

Items: 1 to 50 of 55

1.

Ductal carcinoma in situ of breast: update 2019.

Badve SS, Gökmen-Polar Y.

Pathology. 2019 Oct;51(6):563-569. doi: 10.1016/j.pathol.2019.07.005. Epub 2019 Aug 28. Review.

PMID:
31472981
2.

TP53 Status and Estrogen Receptor-beta in Triple Negative Breast Cancer: Company matters.

Badve S, Gokmen-Polar Y.

J Natl Cancer Inst. 2019 Apr 16. pii: djz052. doi: 10.1093/jnci/djz052. [Epub ahead of print] No abstract available.

PMID:
30989234
3.

Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues.

Chen Y, Shen Q, White SL, Gokmen-Polar Y, Badve S, Goodman LJ.

Sci Rep. 2019 Apr 4;9(1):5624. doi: 10.1038/s41598-019-41957-w.

4.

Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways.

Gökmen-Polar Y, Neelamraju Y, Goswami CP, Gu Y, Gu X, Nallamothu G, Vieth E, Janga SC, Ryan M, Badve SS.

EMBO Rep. 2019 Feb;20(2). pii: e46078. doi: 10.15252/embr.201846078. Epub 2019 Jan 21.

PMID:
30665944
5.

EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.

Buechler SA, Gökmen-Polar Y, Badve SS.

Breast. 2019 Feb;43:74-80. doi: 10.1016/j.breast.2018.11.006. Epub 2018 Nov 17.

PMID:
30502641
6.

HSF1 as a Cancer Biomarker and Therapeutic Target.

Carpenter RL, Gökmen-Polar Y.

Curr Cancer Drug Targets. 2019;19(7):515-524. doi: 10.2174/1568009618666181018162117.

7.

Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.

Gökmen-Polar Y, True JD, Vieth E, Gu Y, Gu X, Qi GD, Mosley AL, Badve SS.

PLoS One. 2018 Oct 2;13(10):e0204658. doi: 10.1371/journal.pone.0204658. eCollection 2018.

8.

EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.

Buechler SA, Gökmen-Polar Y, Badve SS.

Clin Breast Cancer. 2019 Feb;19(1):17-26.e8. doi: 10.1016/j.clbc.2018.07.011. Epub 2018 Jul 17.

PMID:
30097312
9.

The Integrated Genomic Landscape of Thymic Epithelial Tumors.

Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC; Cancer Genome Atlas Network, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ.

Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.

10.

Single-cell heterogeneity in ductal carcinoma in situ of breast.

Gerdes MJ, Gökmen-Polar Y, Sui Y, Pang AS, LaPlante N, Harris AL, Tan PH, Ginty F, Badve SS.

Mod Pathol. 2018 Mar;31(3):406-417. doi: 10.1038/modpathol.2017.143. Epub 2017 Nov 17.

11.

Upregulation of HSF1 in estrogen receptor positive breast cancer.

Gökmen-Polar Y, Badve S.

Oncotarget. 2016 Dec 20;7(51):84239-84245. doi: 10.18632/oncotarget.12438.

12.

Breast cancer prognostic markers: an overview of a changing menu.

Gökmen-Polar Y, Badve S.

MLO Med Lab Obs. 2015 Oct;47(10):8, 10, 12-3; quiz 14. No abstract available.

PMID:
26591252
13.

Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation.

Mneimneh WS, Gökmen-Polar Y, Kesler KA, Loehrer PJ Sr, Badve S.

Mod Pathol. 2015 Nov;28(11):1415-27. doi: 10.1038/modpathol.2015.104. Epub 2015 Sep 11.

14.

Tumor Heterogeneity in Breast Cancer.

Badve S, Gökmen-Polar Y.

Adv Anat Pathol. 2015 Sep;22(5):294-302. doi: 10.1097/PAP.0000000000000074. Review.

PMID:
26262511
15.

Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers.

Gökmen-Polar Y, Vladislav IT, Neelamraju Y, Janga SC, Badve S.

Sci Rep. 2015 Mar 5;5:8765. doi: 10.1038/srep08765.

16.

Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.

Duchnowska R, Jassem J, Goswami CP, Dundar M, Gökmen-Polar Y, Li L, Woditschka S, Biernat W, Sosińska-Mielcarek K, Czartoryska-Arłukowicz B, Radecka B, Tomasevic Z, Stępniak P, Wojdan K, Sledge GW Jr, Steeg PS, Badve S.

J Neurooncol. 2015 Mar;122(1):205-16. doi: 10.1007/s11060-014-1704-y. Epub 2015 Jan 6.

17.

Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer.

Gökmen-Polar Y, Neelamraju Y, Goswami CP, Gu X, Nallamothu G, Janga SC, Badve S.

Mod Pathol. 2015 May;28(5):677-85. doi: 10.1038/modpathol.2014.146. Epub 2014 Nov 28.

18.

Role of lncRNAs in health and disease-size and shape matter.

Mohanty V, Gökmen-Polar Y, Badve S, Janga SC.

Brief Funct Genomics. 2015 Mar;14(2):115-29. doi: 10.1093/bfgp/elu034. Epub 2014 Sep 11. Review.

PMID:
25212482
19.

Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer.

Gökmen-Polar Y, Goswami CP, Toroni RA, Sanders KL, Mehta R, Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW Jr.

J Cancer. 2014 Aug 15;5(8):633-45. doi: 10.7150/jca.8466. eCollection 2014.

20.

Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.

Marino N, Collins JW, Shen C, Caplen NJ, Merchant AS, Gökmen-Polar Y, Goswami CP, Hoshino T, Qian Y, Sledge GW Jr, Steeg PS.

Clin Exp Metastasis. 2014 Oct;31(7):771-86. doi: 10.1007/s10585-014-9667-0. Epub 2014 Aug 3.

21.

DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.

Woditschka S, Evans L, Duchnowska R, Reed LT, Palmieri D, Qian Y, Badve S, Sledge G Jr, Gril B, Aladjem MI, Fu H, Flores NM, Gökmen-Polar Y, Biernat W, Szutowicz-Zielińska E, Mandat T, Trojanowski T, Och W, Czartoryska-Arlukowicz B, Jassem J, Mitchell JB, Steeg PS.

J Natl Cancer Inst. 2014 Jun 19;106(7). pii: dju145. doi: 10.1093/jnci/dju145. Print 2014 Jul.

22.

NUT midline carcinomas in the thymic region.

Gökmen-Polar Y, Cano OD, Kesler KA, Loehrer PJ, Badve S.

Mod Pathol. 2014 Dec;27(12):1649-56. doi: 10.1038/modpathol.2014.63. Epub 2014 May 23.

23.

NUT Midline Carcinoma Masquerading As a Thymic Carcinoma.

Gökmen-Polar Y, Kesler K, Loehrer PJ Sr, Badve S.

J Clin Oncol. 2016 May 10;34(14):e126-9. doi: 10.1200/JCO.2013.51.1741. Epub 2014 Apr 14. No abstract available.

24.

Multiplexed protein analysis.

Gökmen-Polar Y, Badve S.

Sci Transl Med. 2014 Jan 15;6(219):219fs3. doi: 10.1126/scitranslmed.3008407.

PMID:
24431108
25.

The prognostic value of architectural patterns in a study of 37 type AB thymomas.

Vladislav IT, Gökmen-Polar Y, Kesler KA, Loehrer PJ Sr, Badve S.

Mod Pathol. 2014 Jun;27(6):863-8. doi: 10.1038/modpathol.2013.203. Epub 2013 Nov 15.

26.

FOXP3 expression and nodal metastasis of breast cancer.

Gökmen-Polar Y, Thorat MA, Sojitra P, Saxena R, Badve S.

Cell Oncol (Dordr). 2013 Oct;36(5):405-9. doi: 10.1007/s13402-013-0147-3. Epub 2013 Aug 31.

PMID:
23996727
27.

A gene signature to determine metastatic behavior in thymomas.

Gökmen-Polar Y, Cook RW, Goswami CP, Wilkinson J, Maetzold D, Stone JF, Oelschlager KM, Vladislav IT, Shirar KL, Kesler KA, Loehrer PJ Sr, Badve S.

PLoS One. 2013 Jul 24;8(7):e66047. doi: 10.1371/journal.pone.0066047. Print 2013.

28.

The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases.

Vladislav IT, Gökmen-Polar Y, Kesler KA, Loehrer PJ Sr, Badve S.

Mod Pathol. 2013 Aug;26(8):1059-64. doi: 10.1038/modpathol.2013.49. Epub 2013 Apr 12.

29.

Counterpoint: cancer stem cells: nonbelievers' viewpoint.

Gökmen-Polar Y, Badve SS.

Clin Chem. 2013 Jan;59(1):208-10. doi: 10.1373/clinchem.2012.185637. Epub 2012 Nov 7. No abstract available.

30.

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.

Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW Jr.

Breast Cancer Res Treat. 2012 Dec;136(3):673-82. doi: 10.1007/s10549-012-2298-8. Epub 2012 Oct 21.

PMID:
23085766
31.

Breast cancer prognostic markers: where are we now?

Gökmen-Polar Y, Badve S.

MLO Med Lab Obs. 2012 Sep;44(9):22, 24-5. No abstract available.

PMID:
23002506
32.

Establishment and characterization of a novel cell line derived from human thymoma AB tumor.

Gökmen-Polar Y, Sanders KL, Goswami CP, Cano OD, Zaheer NA, Jain RK, Kesler KA, Nelson RP Jr, Vance GH, Smith D, Li L, Cardoso AA, Badve S, Loehrer PJ Sr, Sledge GW Jr.

Lab Invest. 2012 Nov;92(11):1564-73. doi: 10.1038/labinvest.2012.115. Epub 2012 Aug 27.

33.

Molecular analysis of thymoma.

Badve S, Goswami C, Gökmen-Polar Y, Nelson RP Jr, Henley J, Miller N, Zaheer NA, Sledge GW Jr, Li L, Kesler KA, Loehrer PJ Sr.

PLoS One. 2012;7(8):e42669. doi: 10.1371/journal.pone.0042669. Epub 2012 Aug 13.

34.

Molecular profiling assays in breast cancer: are we ready for prime time?

Gökmen-Polar Y, Badve S.

Oncology (Williston Park). 2012 Apr;26(4):350-7, 361. Review. Erratum in: Oncology (Williston Park). 2012 May;26(5):424.

35.

Extrathoracic metastases of thymic origin: a review of 35 cases.

Vladislav T, Jain RK, Alvarez R, Mehta RJ, Gökmen-Polar Y, Kesler KA, Henley JD, Loehrer PJ Sr, Badve S.

Mod Pathol. 2012 Mar;25(3):370-7. doi: 10.1038/modpathol.2011.178. Epub 2011 Nov 11.

36.

Biomarkers for breast cancer stem cells: the challenges ahead.

Gökmen-Polar Y, Nakshatri H, Badve S.

Biomark Med. 2011 Oct;5(5):661-71. doi: 10.2217/bmm.11.57. Review.

PMID:
22003917
37.

Tumor marker assessment: points to ponder.

Gökmen-Polar Y, Badve S.

Cancer Biol Ther. 2011 Jan 15;11(2):284-6. Epub 2011 Jan 15. No abstract available.

PMID:
21178400
38.

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.

Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD.

Breast Cancer Res Treat. 2011 Jun;127(2):375-84. doi: 10.1007/s10549-010-1004-y. Epub 2010 Jul 3.

PMID:
20602165
39.

Promise of computational systems biology for cancer clinical trials: the voyage to be realized?

Gökmen-Polar Y, Badve S.

Per Med. 2010 Mar;7(2):129-131. doi: 10.2217/pme.09.71. No abstract available.

40.

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.

Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S.

Breast Cancer Res Treat. 2010 Nov;124(2):327-35. doi: 10.1007/s10549-010-0733-2. Epub 2010 Jan 23.

PMID:
20099025
41.

Redefining the target again: chemotherapeutics as vascular disrupting agents?

Gokmen-Polar Y, Miller KD.

Cancer Cell. 2008 Sep 9;14(3):195-6. doi: 10.1016/j.ccr.2008.08.006.

42.

2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells.

Bhati R, Gökmen-Polar Y, Sledge GW Jr, Fan C, Nakshatri H, Ketelsen D, Borchers CH, Dial MJ, Patterson C, Klauber-DeMore N.

Cancer Res. 2007 Jan 15;67(2):702-8.

43.

A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells.

Brown DP, Gökmen-Polar Y, Jiang L, Tan J, Ringham H, Janecki DJ, Qi G, Witzmann FA, Sledge GW Jr, Wang M.

Proteomics Clin Appl. 2007 Jan;1(1):18-31. doi: 10.1002/prca.200600171. Epub 2006 Dec 5.

PMID:
21136609
44.

Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.

Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ.

Prostate. 2006 Oct 1;66(14):1498-511.

PMID:
16921510
45.

Protein kinase C-beta as a therapeutic target in breast cancer.

Sledge GW Jr, Gökmen-Polar Y.

Semin Oncol. 2006 Jun;33(3 Suppl 9):S15-8. Review.

PMID:
16797377
46.

beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.

Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW Jr.

Cancer Res. 2005 Oct 15;65(20):9406-14.

47.

Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo.

Murray NR, Jamieson L, Yu W, Zhang J, Gökmen-Polar Y, Sier D, Anastasiadis P, Gatalica Z, Thompson EA, Fields AP.

J Cell Biol. 2004 Mar 15;164(6):797-802.

48.

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.

Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS.

Cancer Res. 2003 Jun 15;63(12):3425-9.

49.

Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.

Gökmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP.

Cancer Res. 2001 Feb 15;61(4):1375-81.

50.

Mapping of a molecular determinant for protein kinase C betaII isozyme function.

Gökmen-Polar Y, Fields AP.

J Biol Chem. 1998 Aug 7;273(32):20261-6.

Supplemental Content

Loading ...
Support Center